Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections

NCT01102387 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Candidiasis

Interventions

DRUG: LAS41003
DRUG: LAS189962
DRUG: LAS189961

Sponsor

Almirall, S.A.